| Literature DB >> 36051734 |
Ruchi Karnatak1, Anjoo Agarwal1, Mona Asnani1, Renu Singh1.
Abstract
Objective To study the status of insulin resistance (IR) in non-polycystic ovary syndrome (PCOS) infertile women and to assess its effects on response to ovulation induction (OI) with clomiphene citrate (CC). Methods and materials A prospective cohort study was conducted at the Department of Obstetrics and Gynecology, King George Medical University, Lucknow, India, over a one-year period. One hundred two women who underwent treatment for infertility were enrolled and evaluated for insulin resistance. Insulin resistance was assessed using fasting serum insulin levels and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index. All participants were given ovulation induction with clomiphene citrate and were then followed up for the occurrence of ovulation and conception. Results Insulin resistance was found in 20.5% of infertile subjects and 95.4% of anovulatory subjects. Of the subjects with insulin resistance, 80.5% showed monofollicular development. The pregnancy rate was 5.8%, but there was no conception among subjects with insulin resistance. Conclusions Insulin resistance was found to be present in 20.5% of infertile women. Women with insulin resistance are more likely to have monofollicular development on ovulation induction and are less likely to conceive as compared with women without insulin resistance (OR = 0.2079).Entities:
Keywords: anovulatory infertility; clomiphene citrate; insulin resistance; ovulation induction; prospective cohort study
Year: 2022 PMID: 36051734 PMCID: PMC9420237 DOI: 10.7759/cureus.27433
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Distribution of HOMA-IR values in the study population
Mean = 1.49 ± 0.95
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance
| Serial number | HOMA-IR | Number of women | Percentage (%) |
| 1 | <1 | 25 | 24.5 |
| 2 | 1–1.9 | 56 | 54.9 |
| 3 | 2–2.9 | 18 | 17.6 |
| 4 | ≥ 3 | 3 | 2.9 |
| Total | 102 | 100 |
Correlation between BMI and HOMA-IR
chi-square=30; p<0.001
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; BMI: body mass index
| Serial number | BMI (kg/m2) | Total number of women | Number of women HOMA-IR ≥2 | Percentage (%) | Relative risk of insulin resistance | 95%confidence Interval | P-value |
| 1 | <18.5 | 0 | 0 | 0 | |||
| 2 | 18.5–22.9 | 46 | 1 | 2.1 | |||
| 3 | 23–24.9 | 20 | 2 | 10 | 4.6 | 0.4-47.8 | 0.20 |
| 4 | ≥25 | 36 | 18 | 50 | 23 | 3.2-164.2 | <0.0018 |
| Total | 102 | 21 |
Correlation of the waist-hip ratio with HOMA-IR
Chi-square 32.1, p<0.001
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance
| Serial number | Waist: hip ratio | Number of women | Number of women with HOMA-IR ≥2 | Percentage (%) | Relative risk of insulin resistance | 95% confidence interval | P-value |
| 1 | <0.80 | 42 | 1 | 2.3 | |||
| 2 | 0.80–0.84 | 22 | 1 | 4.5 | 1.9 | 0.12–29.0 | 0.6 |
| 3 | ≥0.85 | 38 | 19 | 50 | 21 | 2.95–149.4 | 0.0024 |
| Total | 102 | 21 |
Distribution of women based on conception
| S. No. | Conception | Number of women N=102 |
| 1 | No | 96 |
| 2 | Yes | 6 |
Distribution of conceived women based on number of developing follicles
| Number of women conceived out of all women (n=102) | Number of women conceived out of women who developed 1 follicle (n=55) | Number of women conceived out of women who developed 2 follicles (n=41) | Number of women conceived out of women who developed 3 follicles (n=6) |
| 6 | 0 (0%) | 5 (12.2%) | 1 (16.6%) |
Correlation of number of dominant follicles ratio with HOMA-IR ≥2 (n=102)
chi-square=7.77, p-value=0.005
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance
| S no. | No. of dominant follicles | No. of total women | No. of women with HOMA IR≥2 | Percentage of women with HOMA IR>2 out of total women |
| 1 | 1 | 55 | 17 | 30.9 |
| 2 | 2 | 41 | 3 | 7.3 |
| 3 | 3 | 6 | 1 | 16.6 |
| Total | 102 | 21 |
Correlation of S. AMH with HOMA-IR ≥2 (n=102)
Chi square=19.5, p value=<0.001
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; S. AMH: serum anti-Müllerian hormone
| S no. | S AMH (ng/ml) | No. of women | HOMA-IR≥2 | % | Relative risk | |
| 1 | <1.0 | 0 | 0 | 0 | ||
| 2 | 1.0-3.9 | 58 | 3 | 5.1 | ||
| 3 | ≥4 | 44 | 18 | 40.9 | 7.9 (95% CI 2.4-25.1 p=0.0005) | |
| Total | 102 | 21 |